نتایج جستجو برای: eptifibatide
تعداد نتایج: 434 فیلتر نتایج به سال:
L eft ventricular assist device (LVAD) thrombosis is a life-threatening complication occurring in ≈6% of patients receiving a HeartMate II (HMII) LVAD (Thoratec Corp, Pleasanton, CA) within 24 months after implantation. 1 Prophylactic therapy with aspirin and warfarin to an international normalized ratio (INR) of 1.5 to 2.5 is recommended to prevent LVAD thrombosis in most HMII recipients. 2 Fo...
BACKGROUND AND PURPOSE Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The combined approach to lysis utilizing eptifiba...
Thromb Haemost 2005; 94: 693–4 Coronary no-reflow is a rare but potentially devastating complication that can occur during percutaneous coronary interventions (PCI). It is defined as the lack of passage of contrast dye into the microvasculature despite relief of the original obstruction in the epicardial vessel and is an angiographic marker of impaired myocardial perfusion at the tissue level (...
The acute coronary syndrome due to the left main coronary artery (LMCA) thrombosis is a clinically rare and catastrophic event. We describe a young man (smoker, alcoholic, and drug abuser) with a history of recent surgery and typical chest pain who had non-occlusive LMCA thrombosis in coronary angiography. The thrombosis was successfully treated with two 180 µ/kg intracoronary boluses of eptifi...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید